These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 30200779)

  • 41. A network meta-analysis of antibiotics for treatment of hospitalised patients with suspected or proven meticillin-resistant Staphylococcus aureus infection.
    Bally M; Dendukuri N; Sinclair A; Ahern SP; Poisson M; Brophy J
    Int J Antimicrob Agents; 2012 Dec; 40(6):479-95. PubMed ID: 23102749
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.
    Prokocimer P; De Anda C; Fang E; Mehra P; Das A
    JAMA; 2013 Feb; 309(6):559-69. PubMed ID: 23403680
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Skin and soft-tissue infections: a critical review and the role of telavancin in their treatment.
    Cardona AF; Wilson SE
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S69-78. PubMed ID: 26316560
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In Vitro activities of Tedizolid and comparator antimicrobial agents against clinical isolates of Staphylococcus aureus collected in 12 countries from 2014 to 2016.
    Karlowsky JA; Hackel MA; Bouchillon SK; Alder J; Sahm DF
    Diagn Microbiol Infect Dis; 2017 Oct; 89(2):151-157. PubMed ID: 28793964
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term Use of Tedizolid as Suppressive Therapy for Recurrent Methicillin-Resistant Staphylococcus aureus Graft Infection.
    Nigo M; Luce AM; Arias CA
    Clin Infect Dis; 2018 Jun; 66(12):1975-1976. PubMed ID: 29370350
    [No Abstract]   [Full Text] [Related]  

  • 46. New developments in the management of severe skin and deep skin structure infections - focus on tedizolid.
    Durkin MJ; Corey GR
    Ther Clin Risk Manag; 2015; 11():857-62. PubMed ID: 26045667
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tedizolid: a service evaluation in a large UK teaching hospital.
    York JA; Adams K; Cullen L; Delahay J; Ivan M; Lillie PJ; MacLachlan L; Barlow G
    Eur J Clin Microbiol Infect Dis; 2021 Feb; 40(2):397-405. PubMed ID: 32851509
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Empirical therapy in Methicillin-resistant Staphylococcus Aureus infections: An Up-To-Date approach.
    VanEperen AS; Segreti J
    J Infect Chemother; 2016 Jun; 22(6):351-9. PubMed ID: 27066882
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis.
    Itani KM; Biswas P; Reisman A; Bhattacharyya H; Baruch AM
    Clin Ther; 2012 Aug; 34(8):1667-73.e1. PubMed ID: 22770644
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France.
    De Cock E; Sorensen S; Levrat F; Besnier JM; Dupon M; Guery B; Duttagupta S
    Med Mal Infect; 2009 May; 39(5):330-40. PubMed ID: 19304423
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The times they are a-changin': new antibacterials for skin and skin structure infections.
    Tran MC; Naumovski S; Goldstein EJ
    Am J Clin Dermatol; 2015 Jun; 16(3):137-46. PubMed ID: 25906205
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Methicillin-resistant Staphylococcus aureus infections: A review of the currently available treatment options.
    Purrello SM; Garau J; Giamarellos E; Mazzei T; Pea F; Soriano A; Stefani S
    J Glob Antimicrob Resist; 2016 Dec; 7():178-186. PubMed ID: 27889013
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Linezolid versus vancomycin for skin and soft tissue infections.
    Yue J; Dong BR; Yang M; Chen X; Wu T; Liu GJ
    Cochrane Database Syst Rev; 2013 Jul; (7):CD008056. PubMed ID: 23846850
    [TBL] [Abstract][Full Text] [Related]  

  • 54. European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid.
    Chastre J; Blasi F; Masterton RG; Rello J; Torres A; Welte T
    Clin Microbiol Infect; 2014 Apr; 20 Suppl 4():19-36. PubMed ID: 24580739
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of Translational Pharmacokinetic/Pharmacodynamic Infection Models To Understand the Impact of Neutropenia on the Efficacy of Tedizolid Phosphate.
    Xiao J; Gill C; Liang L; Liu J; Wu J; Feng HP; Flanagan S; Tan C; Flattery A
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373794
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus.
    Itani KM; Dryden MS; Bhattacharyya H; Kunkel MJ; Baruch AM; Weigelt JA
    Am J Surg; 2010 Jun; 199(6):804-16. PubMed ID: 20227056
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Methicillin-resistant Staphylococcus aureus therapy: past, present, and future.
    Rodvold KA; McConeghy KW
    Clin Infect Dis; 2014 Jan; 58 Suppl 1():S20-7. PubMed ID: 24343828
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tedizolid for the management of human infections: in vitro characteristics.
    Locke JB; Zurenko GE; Shaw KJ; Bartizal K
    Clin Infect Dis; 2014 Jan; 58 Suppl 1():S35-42. PubMed ID: 24343830
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of infections due to resistant Staphylococcus aureus.
    Anstead GM; Cadena J; Javeri H
    Methods Mol Biol; 2014; 1085():259-309. PubMed ID: 24085702
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: efficacy summary.
    O'Riordan W; Green S; Mehra P; De Anda C; Fang E; Prokocimer P
    Clin Infect Dis; 2014 Jan; 58 Suppl 1():S43-50. PubMed ID: 24343832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.